Skip to main content
Fig. 8 | Respiratory Research

Fig. 8

From: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

Fig. 8

Total costs following FF/UMEC/VI initiation. FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol, GP general practitioner, A&E Accident and Emergency, CI confidence interval, COPD chronic obstructive pulmonary disease. p-values in bold text indicate statistical significance

Back to article page